Tumor-specific CD4+ T cell (CD4+ T cell)

Tumor-specific CD4+ T cells are a specialized subset of helper T lymphocytes that recognize tumor-associated antigens or neoantigens presented on Major Histocompatibility Complex (MHC) class II molecules (Borst et al., 2018). These cells act as central orchestrators of the anti-tumor immune response by providing essential signals for the activation and memory formation of CD8+ cytotoxic T cells and directly secreting pro-inflammatory cytokines such as interferon-gamma (IFN-gamma) (Tay et al., 2021). In the tumor microenvironment, these cells often encounter immunosuppressive signals that lead to a state of exhaustion, which can be therapeutically reversed using immune checkpoint inhibitors like anti-PD-1 or anti-CTLA-4 antibodies (Topalian et al., 2012; Hodi et al., 2010). Furthermore, tumor-specific CD4+ T cells are increasingly utilized in adoptive cell transfer (ACT) and personalized cancer vaccines, where their expansion and activation are leveraged to achieve durable clinical responses (Sahin & Türeci, 2018). Their presence and functional status within the tumor microenvironment are critical determinants of clinical outcomes and serve as key biomarkers for predicting patient response to various immunotherapies.

Other names

Helper T cellTh cellTumor-infiltrating CD4+ lymphocyteCD4+ tumor-reactive T cellMHC class II-restricted T cell

Modulation of T-cell activation and exhaustion through checkpoint inhibition or antigen-specific stimulation.